Melinta Therapeutics Inc. (NASDAQ:MLNT)
Old Forum Content for MLNTMake a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- woodman: @spmeyers $TTPH $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO #Antibiotics - I think your paramaters for/definition of a break of the 50 day are too precise. The way I look at it, it has held the 50 day.
- woodman: $TTPH - In a good spot here. Buy the dips, sell the rips on this one. New #Antibiotics bill may pull up the entire antibiotics sector if it gets traction. This is regarded as an important bill. http://www.cidrap.umn.edu/news-perspective/2018/06/bipartisan-bill-proposes-new-pull-incentives-priority-antibiotics Other antibiotics stocks: $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO
- steve71: @woodman $TTPH $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO #Antibiotics That Prize concept is really interesting. A problem not mentioned is that new antibiotics are often barely used in order to protect them from rapid resistance. Sometimes they are available only in hospital and only after an Infectious Disease consult. With low volumes, it may take a decade to recover development costs. But using the Prize to extend exclusivity on other more profitable drugs is a smart inducement. Would be good to see the potential gains quantified.
- woodman: @steve71 $TTPH $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO #Antibiotics - Thanks for your thoughts, as always. Check out the intraday chart for TTPH today.
- spmeyers: @woodman $TTPH $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO #Antibiotics thx for that list to watch; break of 50-day concerns me on TTPH though
- woodman: #Antibiotics companies $AKAO $NBRV $TTPH $MTFB $PRTK $MLNT $CDTX $SCYX $SPRO: FDA and CMS under discussion for new reimbursement model to create incentives for the development of novel antimicrobial drugs. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm610503.htm Very interesting news for antibiotics stocks.
|Stock Price||$USD 3.98|
Melinta Therapeutics Inc is a commercial-stage biopharmaceutical company. It is developing antibiotic, Baxdela (delafloxacin), for the treatment of adults with serious skin infections known as acute bacterial skin and skin structure infections.Request Video of MLNT
Already a member? Sign in here.
- August 7th, 2019 - 2019 Q2 Earnings
- $USD 16.02 57.00%
- $USD 49.41 53.39%
- $USD 6.05 52.19%
- $USD 31.58 -34.27%
- $USD 15.13 -34.20%
- $USD 10.20 -30.37%
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 14 day FREE membership. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 63,700 stock analysis videos
- Access an ever expanding library (63,700) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Your Stock Market Mentor membership comes with a 14 day, no questions asked, 100% money back guarantee!